Can you identify these newer medications available to treat heart failure or hypertension? Match the medications in Section I with the description in Section II.

Section I

_____ 1. Entresto (Novartis)

_____ 2. Edarbi (Arbor Pharmaceuticals)

_____ 3. Prestalia (Symplmed)

_____ 4. Corlanor (Amgen Inc.)

Section II

a. ivabradine. Taken twice a day, this drug is indicated to reduce the risk of hospitalization for worsening heart failure (HF) in select patients who are either on maximum beta-blocker therapy or who have a contraindication to beta-blocker use. Monitor patients for cardiac dysrhythmias and hypertension.

b. azilsartan. This once-daily angiotensin II receptor blocker (ARB) is indicated to treat hypertension. It can be used as monotherapy or in combination with other antihypertensive agents. Monitor for worsening renal function in patients with renal impairment.

c. sacubitril/valsartan. Taken twice daily, this drug is a combination of a neprilysin inhibitor and an ARB. It's used to reduce risk of cardiovascular death and hospitalization for patients with New York Heart Association Class II-IV HF. It's usually administered in conjunction with other HF therapies, in place of either an angiotensin converting enzyme (ACE) inhibitor or an ARB. It carries a boxed warning for fetal toxicity.

d. perindopril/amlodipine. Indicated to treat hypertension, this once-daily medication combines an ACE inhibitor and a dihydropyridine calcium channel blocker. Assess for hypotension and hyperkalemia, as well as for anaphylactoid reactions, including angioedema.

ANSWERS: 1c, 2b, 3d, 4a